165 related articles for article (PubMed ID: 37521522)
1. Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.
Erickson CM; Chin NA; Rosario HL; Peterson A; Johnson SC; Clark LR
Alzheimers Dement (N Y); 2023; 9(3):e12413. PubMed ID: 37521522
[TBL] [Abstract][Full Text] [Related]
2. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
3. Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.
Grill JD; Raman R; Ernstrom K; Wang S; Donohue MC; Aisen PS; Karlawish J; Henley D; Romano G; Novak G; Brashear HR; Sperling RA
Neurol Clin Pract; 2024 Apr; 14(2):e200265. PubMed ID: 38585443
[TBL] [Abstract][Full Text] [Related]
4. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
5. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
[TBL] [Abstract][Full Text] [Related]
6. The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants.
Erickson CM; Chin NA; Ketchum FB; Eveler ML; Conway CE; Coughlin DM; Clark LR
J Prev Alzheimers Dis; 2024; 11(1):1-6. PubMed ID: 38230711
[TBL] [Abstract][Full Text] [Related]
7. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
[TBL] [Abstract][Full Text] [Related]
8. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
9. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
10. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Erickson CM; Chin NA; Johnson SC; Gleason CE; Clark LR
Alzheimers Dement (Amst); 2021; 13(1):e12150. PubMed ID: 33665341
[TBL] [Abstract][Full Text] [Related]
11. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
[TBL] [Abstract][Full Text] [Related]
12. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
13. Safety of disclosing amyloid status in cognitively normal older adults.
Burns JM; Johnson DK; Liebmann EP; Bothwell RJ; Morris JK; Vidoni ED
Alzheimers Dement; 2017 Sep; 13(9):1024-1030. PubMed ID: 28263740
[TBL] [Abstract][Full Text] [Related]
14. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Ritchie M; Salazar CR; Gillen DL; Grill JD
Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
[TBL] [Abstract][Full Text] [Related]
15. Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults.
Babulal GM; Roe CM; Stout SH; Rajasekar G; Wisch JK; Benzinger TLS; Morris JC; Ances BM
J Alzheimers Dis; 2020; 74(4):1045-1055. PubMed ID: 32144985
[TBL] [Abstract][Full Text] [Related]
16. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
18. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
20. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
